Goldman Sachs Says Not So Fast On Pharmasset (VRUS)
Tweet Send to a FriendGet Alerts VRUS Hot Sheet
Price: $136.97 --0%
Rating Summary:
5 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
5 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade VRUS Now!
Analysts at Goldman Sachs issued more cautious comments on Pharmasset, Inc. (Nasdaq: VRUS), which has surged recently after an bullish abstracts from EASL from a combo study of PSI-7977 and PSI-938 was posted online.
Goldman anticipates this combo to yield a high response rate, but states "while the VRUS combo data should be interesting, they still do not answer the "billion dollar" question in hepC – if it is possible to generate SVR's (cures) with an all oral combo regimen without PEG-interferon."
Goldman also states a number of hurdles remain as they believe that nucs must successfully demonstrate: "(1) the ability to suppress virus over longer treatment durations (>14 days) without interferon, (2) tolerability over longer treatment durations in more patients, and (3) comparable or better relapse rates (particularly in early responders, eRVR patients) to protease and non-nuc polymerase regimens."
The firm maintained their Neutral rating on Pharmasset, which jumped 24% yesterday and is up another 8% today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Goldman anticipates this combo to yield a high response rate, but states "while the VRUS combo data should be interesting, they still do not answer the "billion dollar" question in hepC – if it is possible to generate SVR's (cures) with an all oral combo regimen without PEG-interferon."
Goldman also states a number of hurdles remain as they believe that nucs must successfully demonstrate: "(1) the ability to suppress virus over longer treatment durations (>14 days) without interferon, (2) tolerability over longer treatment durations in more patients, and (3) comparable or better relapse rates (particularly in early responders, eRVR patients) to protease and non-nuc polymerase regimens."
The firm maintained their Neutral rating on Pharmasset, which jumped 24% yesterday and is up another 8% today.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- VIVUS (VVUS) Qsymia Prescriptions Fall Ahead of Belviq Launch (ARNA)
- Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
